skip to Main Content

Addition of Onivyde to Standard Care Improves Survival, Does Not Worsen Quality of Life in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The addition of Onivyde (MM-398) to 5-fluorouracil (5-FU) and leucovorin significantly improved overall survival (OS) while having no negative impact on quality of life (QOL) for patients with metastatic pancreatic cancer, according to an analysis of the phase 3 NAPOLI-1 trial presented at the 2016 World Congress on Gastrointestinal (GI) Cancer, a gathering of oncology professionals from around the world in Barcelona, Spain.

“This quality of life analysis of the NAPOLI-1 data underscores the significant clinical benefit the Onivyde regimen provides to a patient population with few treatment options,” Richard Hubner, an investigator on the NAPOLI-1 trial and Consultant Medical Oncologist at Christie NHS Foundation Trust, said in a statement. Read more . . .

Back To Top